←
Memorial Sloan Kettering Cancer Center27,300 posts
Memorial Sloan Kettering Cancer Center avatar

Memorial Sloan Kettering Cancer Center

@MSKCancerCenter

Where you’re treated first, matters. To make an appointment: 877-871-9362

◷ Joined March 2009▧ 6,837 Photos and videos
Memorial Sloan Kettering Cancer Center avatar
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·22h

🚨 A new cancer vaccine appears to significantly improve survival in people in remission from acute myeloid leukemia (AML), according to new results from a phase 3 clinical trial. The vaccine, galinpepimut-S (GPS), is an “off-the-shelf” vaccine invented by MSK leukemia specialist and physician-scientist Dr. David A. Scheinberg (@DASLab_MSKCC). In the trial of 126 patients, it reduced the risk of death by 41%. Median overall survival was 24.0 months with the vaccine compared with 14.7 months for patients on standard treatments. “These data bring us closer to having the first off-the-shelf vaccine for AML patients." Learn more: bit.ly/4fDoAmS

Post attachment
David H Aggen, MD PhD avatar
⟳ Memorial Sloan Kettering Cancer Center retweeted
David H Aggen, MD PhD@Dr_Aggen·Nov 16

Trials are critical for defining what comes after EV + pembrolizumab (EV/P) in advanced bladder cancer? 🧵 1/9 At @MSKCancerCenter with @MSK_DeptOfMed @UrologyMSK we're exploring all these approaches through several clinical trials to overcome EV resistance New Patients Contact for appointments: 866-432-3416 mskcc.org/experience/become-… - NEW cancer targets (TROP2, EGFR/HER3) - NEW ADC payloads (Topo-I) - T-cell engagers - Radioligand therapies @MSK_DeptOfMed #blcsm

Post attachment
DAVA Oncology avatar
⟳ Memorial Sloan Kettering Cancer Center retweeted
DAVA Oncology@DAVAOnc·Nov 14

Can biomarkers inform RT de-escalation in HPV+ oropharyngeal cancer? At #DAVAHeadAndNeck, Dr. Eric Sherman (@MSKCancerCenter) reviewed selected cohorts: 5-year PFS 90% with 30 Gy vs 89% with 70 Gy (median follow-up 4.1 years).

Post attachmentPost attachmentPost attachmentPost attachment
Memorial Sloan Kettering Cancer Center avatar
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·Nov 13

Our Summer at Memorial Sloan Kettering Cancer Center (MSK) research programs are now open to current sophomores and juniors interested in biomedicine, chemistry, computational biology, and engineering. These in-person programs in NYC offer students the opportunity to gain research experience, build new skills, expand their scientific knowledge, and explore STEM career paths. Learn more at: bit.ly/4zDi2Mx

Post attachment
Memorial Sloan Kettering Cancer Center avatar
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·Nov 12

Researchers at MSK have developed a new computational approach to better understand why #Tcells, the immune system’s primary cancer-fighting cells, respond differently to immunotherapies. Led by computational oncologists @bengrbm and @SohrabShah, the team created a statistical model called TCRi that links a T cell’s unique receptor sequence to its biological behavior, helping reveal how these cells recognize and react to cancer. By analyzing more than 167,000 T cells from patients treated with checkpoint inhibitor immunotherapies, the researchers aimed to uncover how a T cell’s genetic identity influences its activity and how those behaviors change during treatment, potentially improving the ability to predict which patients will benefit from immunotherapy. “This approach produces a standardized measurement that lets us compare results across different studies and clinical trials,” Dr. Greenbaum says. “We have a way to learn from this data what a meaningful T cell response to an immunotherapy looks like — or doesn’t.” Learn more about this research: bit.ly/48yVscR

Post attachment
Memorial Sloan Kettering Cancer Center avatar
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·Nov 11

In a phase 1/2 trial led by MSK thoracic medical oncologist Dr. Kathryn Arbour, more than 30% of patients with previously treated metastatic lung cancer responded to daraxonrasib, meaning their tumors shrank. Learn how daraxonrasib targets multiple KRAS mutations and what the early findings could mean for people with lung cancer: bit.ly/4j9N8WI

Post attachment
Caleb Lareau avatar
⟳ Memorial Sloan Kettering Cancer Center retweeted
Caleb Lareau@CalebLareau·Nov 9

Our bodies are colonized by trillions of viruses that we live with in homeostasis. The most diverse and abundant of these viral families are anelloviruses. A new paper from us at @MSKCancerCenter explores what happens after we *all* have been infected biorxiv.org/content/10.64898… 1/n

Memorial Sloan Kettering Cancer Center avatar
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·Nov 9

MSK will be hosting a Virtual Residency Information Session for our PGY2 Oncology Pharmacy Residency Programs (Adult and Pediatrics) on Tuesday, November 24 at 5pm ET. During these sessions we will provide an overview of our programs and answer any questions you may have. This is also an excellent opportunity to meet our program directors. Register here: bit.ly/4faNASb

Post attachment
Memorial Sloan Kettering Cancer Center avatar
Memorial Sloan Kettering Cancer Center@MSKCancerCenter·Nov 3

“The promise of AI to transform biology is real, and it’s important — but it needs to be done right. MSK computational biologist Dr. Christina Leslie discusses how AI could help design better therapies and decode why tumors resist treatment. Learn more: bit.ly/4AbPMkF

Post attachment